Literature DB >> 25124473

FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer.

Yanli Jin1, Bingchen Han, Jiongyu Chen, Ruprecht Wiedemeyer, Sandra Orsulic, Shikha Bose, Xiao Zhang, Beth Y Karlan, Armando E Giuliano, Yukun Cui, Xiaojiang Cui.   

Abstract

BACKGROUND: Human basal-like breast cancer (BLBC) has a poor prognosis and is often identified by expression of the epidermal growth factor receptor (EGFR). BLBC remains a major clinical challenge because its pathogenesis is not well understood, thus hindering efforts to develop targeted therapies. Recent data implicate the forkhead box C1 (FOXC1) transcription factor as an important prognostic biomarker and functional regulator of BLBC, but its regulatory mechanism and impact on BLBC tumorigenesis remain unclear.
METHODS: The association between FOXC1 and EGFR expression in human breast cancer was examined by immunohistochemistry in formalin-fixed tissues and analysis of the TCGA database. The regulation of FOXC1 by EGFR activation was investigated in MDA-MB-468 cells using immunoblotting, qRT-PCR, and luciferase activity assays. This EGFR effect on FOXC1 expression was confirmed using the MDA-MB-468 xenograft model.
RESULTS: Both FOXC1 mRNA and protein levels significantly correlated with EGFR expression in human breast tumors. EGFR activation induced FOXC1 transcription through the ERK and Akt pathways in BLBC. EGFR inhibition in vivo reduced FOXC1 expression in xenograft tumors. We also found that FOXC1 knockdown impaired the effects of EGF on BLBC cell proliferation, migration, and invasion.
CONCLUSIONS: Our findings uncover a novel EGFR-FOXC1 signaling axis critical for BLBC cell functions, supporting the notion that intervention in the FOXC1 pathway may provide potential modalities for BLBC treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25124473      PMCID: PMC4237705          DOI: 10.1245/s10434-014-3980-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  40 in total

1.  Sequence analysis of mutations and translocations across breast cancer subtypes.

Authors:  Shantanu Banerji; Kristian Cibulskis; Claudia Rangel-Escareno; Kristin K Brown; Scott L Carter; Abbie M Frederick; Michael S Lawrence; Andrey Y Sivachenko; Carrie Sougnez; Lihua Zou; Maria L Cortes; Juan C Fernandez-Lopez; Shouyong Peng; Kristin G Ardlie; Daniel Auclair; Veronica Bautista-Piña; Fujiko Duke; Joshua Francis; Joonil Jung; Antonio Maffuz-Aziz; Robert C Onofrio; Melissa Parkin; Nam H Pho; Valeria Quintanar-Jurado; Alex H Ramos; Rosa Rebollar-Vega; Sergio Rodriguez-Cuevas; Sandra L Romero-Cordoba; Steven E Schumacher; Nicolas Stransky; Kristin M Thompson; Laura Uribe-Figueroa; Jose Baselga; Rameen Beroukhim; Kornelia Polyak; Dennis C Sgroi; Andrea L Richardson; Gerardo Jimenez-Sanchez; Eric S Lander; Stacey B Gabriel; Levi A Garraway; Todd R Golub; Jorge Melendez-Zajgla; Alex Toker; Gad Getz; Alfredo Hidalgo-Miranda; Matthew Meyerson
Journal:  Nature       Date:  2012-06-20       Impact factor: 49.962

2.  The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression.

Authors:  Steven T Sizemore; Ruth A Keri
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

3.  Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.

Authors:  James M Haughian; Mauricio P Pinto; J Chuck Harrell; Brian S Bliesner; Kristiina M Joensuu; Wendy W Dye; Carol A Sartorius; Aik Choon Tan; Päivi Heikkilä; Charles M Perou; Kathryn B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

4.  BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.

Authors:  D Tkocz; N T Crawford; N E Buckley; F B Berry; R D Kennedy; J J Gorski; D P Harkin; P B Mullan
Journal:  Oncogene       Date:  2011-11-28       Impact factor: 9.867

5.  Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.

Authors:  Partha S Ray; Sanjay P Bagaria; Jinhua Wang; Jaime M Shamonki; Xing Ye; Myung-Shin Sim; Shawn Steen; Ying Qu; Xiaojiang Cui; Armando E Giuliano
Journal:  Ann Surg Oncol       Date:  2011-03-18       Impact factor: 5.344

6.  Prognostic value of basal phenotype in HER2-overexpressing breast cancer.

Authors:  Sanjay P Bagaria; Partha S Ray; Jinhua Wang; Luisa Kropcho; Alice Chung; Myung-Shin Sim; Jaime M Shamonki; Silvana Martino; Xiaojiang Cui; Armando E Giuliano
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

Review 7.  Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.

Authors:  Libero Santarpia; Scott M Lippman; Adel K El-Naggar
Journal:  Expert Opin Ther Targets       Date:  2012-01-12       Impact factor: 6.902

8.  CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression.

Authors:  Tang Jiang; Brian Grabiner; Yifan Zhu; Changying Jiang; Hongxiu Li; Yun You; Jingyu Lang; Mien-Chie Hung; Xin Lin
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

9.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.

Authors:  Joseph H Taube; Jason I Herschkowitz; Kakajan Komurov; Alicia Y Zhou; Supriya Gupta; Jing Yang; Kimberly Hartwell; Tamer T Onder; Piyush B Gupta; Kurt W Evans; Brett G Hollier; Prahlad T Ram; Eric S Lander; Jeffrey M Rosen; Robert A Weinberg; Sendurai A Mani
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

10.  Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.

Authors:  Aslaug Aa Muggerud; Jo Anders Rønneberg; Fredrik Wärnberg; Johan Botling; Florence Busato; Jovana Jovanovic; Hiroko Solvang; Ida Bukholm; Anne-Lise Børresen-Dale; Vessela N Kristensen; Therese Sørlie; Jörg Tost
Journal:  Breast Cancer Res       Date:  2010-01-07       Impact factor: 6.466

View more
  22 in total

1.  Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

Authors:  Alice Chung; Michael Choi; Bing-chen Han; Shikha Bose; Xiao Zhang; Lali Medina-Kauwe; Jessica Sims; Ramachandran Murali; Michael Taguiam; Marian Varda; Rachel Schiff; Armando Giuliano; Xiaojiang Cui
Journal:  Clin Breast Cancer       Date:  2015-06-19       Impact factor: 3.225

2.  FOXC1 Negatively Regulates DKK1 Expression to Promote Gastric Cancer Cell Proliferation Through Activation of Wnt Signaling Pathway.

Authors:  Jiang Jiang; Jianfang Li; Weiwu Yao; Wenfang Wang; Bowen Shi; Fei Yuan; Jingyan Dong; Huan Zhang
Journal:  Front Cell Dev Biol       Date:  2021-04-27

3.  MicroRNA-495 downregulates FOXC1 expression to suppress cell growth and migration in endometrial cancer.

Authors:  Yan-Ying Xu; Jing Tian; Quan Hao; Li-Rong Yin
Journal:  Tumour Biol       Date:  2015-07-22

4.  FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.

Authors:  Y L Xu; R Yao; J Li; Y D Zhou; F Mao; B Pan; Q Sun
Journal:  Cancer Chemother Pharmacol       Date:  2017-05-10       Impact factor: 3.333

5.  Identification of EGF-NF-κB-FOXC1 signaling axis in basal-like breast cancer.

Authors:  Stacey Chung; Yanli Jin; Bingchen Han; Ying Qu; Bowen Gao; Armando E Giuliano; Xiaojiang Cui
Journal:  Cell Commun Signal       Date:  2017-06-19       Impact factor: 5.712

6.  BCIP: a gene-centered platform for identifying potential regulatory genes in breast cancer.

Authors:  Jiaqi Wu; Shuofeng Hu; Yaowen Chen; Zongcheng Li; Jian Zhang; Hanyu Yuan; Qiang Shi; Ningsheng Shao; Xiaomin Ying
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

7.  FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.

Authors:  Jeff Johnson; Michael Choi; Farnaz Dadmanesh; Bingchen Han; Ying Qu; Yi Yu-Rice; Xiao Zhang; Sanjay Bagaria; Clive Taylor; Armando E Giuliano; Farin Amersi; Xiaojiang Cui
Journal:  Oncotarget       Date:  2016-11-15

8.  Knockdown of long non-coding RNA XIST increases blood-tumor barrier permeability and inhibits glioma angiogenesis by targeting miR-137.

Authors:  H Yu; Y Xue; P Wang; X Liu; J Ma; J Zheng; Z Li; Z Li; H Cai; Y Liu
Journal:  Oncogenesis       Date:  2017-03-13       Impact factor: 7.485

Review 9.  Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.

Authors:  Ping Wee; Zhixiang Wang
Journal:  Cancers (Basel)       Date:  2017-05-17       Impact factor: 6.639

10.  Tumor Hypoxia Regulates Forkhead Box C1 to Promote Lung Cancer Progression.

Authors:  Yu-Jung Lin; Woei-Cherng Shyu; Chi-Wei Chang; Chi-Chung Wang; Chung-Pu Wu; Hsu-Tung Lee; Liang-Jwu Chen; Chia-Hung Hsieh
Journal:  Theranostics       Date:  2017-03-05       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.